Abiopharma

🔍 L1 Capital Pty Ltd (Executive)

Company: Anteris Technologies Global Corp. (AVR)

Report Date: 2026-07-29

Detailed Transactions and Holdings:

• Sold 155,505 shares of Common Stock at $8.04 per share (Direct)
  Date: 2026-07-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,191,947.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 558,633 shares of Common Stock at $8.2 per share (Direct)
  Date: 2026-07-30 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,633,314.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 5,359,470 shares of CHESS Depository Interests (Derivative)
  Date: 2026-07-29 | Code: H | shares_owned_after: 5,359,470.00 | Footnotes: F1, F4, F4, F5, F3

Footnotes:

• F1: In submitting this Form 4, the Reporting Person does not admit that it is obligated to file ownership reports under the Securities Exchange Act of 1934 since it is exempt under Rule 16a-2.
• F2: The shares were sold in multiple transactions at prices ranging from $8.03 - $8.06. Upon request, full information regarding the number of shares sold at each separate price can be provided.
• F3: The shares are owned by the L1 Long Short Fund Limited, the L1 Capital Long Short Fund, the L1 Capital Long Short (Master) Fund, L1 Capital Global Long Short (Master) Fund, L1 Capital Global Long Short Fund, L1 Capital Global Long Short (AUD Offshore) Fund and L1 Global Long Short Fund Limited, all controlled and managed by L1 Capital Pty Ltd.
• F4: The CHESS Depository Interests represent one underlying share of the Issuers common stock and are exchangeable for shares of the Issuers common stock within 60 days.
• F5: Not applicable